E Fund Management Hong Kong Co. Ltd. Has $48,000 Stock Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

E Fund Management Hong Kong Co. Ltd. decreased its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 30.5% in the 1st quarter, Holdings Channel.com reports. The firm owned 114 shares of the company’s stock after selling 50 shares during the quarter. E Fund Management Hong Kong Co. Ltd.’s holdings in IDEXX Laboratories were worth $48,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in IDXX. Hurley Capital LLC acquired a new position in shares of IDEXX Laboratories during the fourth quarter worth $29,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories during the 4th quarter worth $30,000. Colonial Trust Co SC increased its holdings in IDEXX Laboratories by 84.8% in the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company’s stock worth $35,000 after purchasing an additional 39 shares in the last quarter. Itau Unibanco Holding S.A. increased its holdings in IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company’s stock worth $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC raised its position in IDEXX Laboratories by 40.0% in the first quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company’s stock valued at $44,000 after purchasing an additional 30 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Trading Up 0.1%

NASDAQ:IDXX opened at $524.65 on Tuesday. The firm’s fifty day moving average is $489.21 and its 200-day moving average is $448.49. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. IDEXX Laboratories, Inc. has a 52 week low of $356.14 and a 52 week high of $530.73. The firm has a market cap of $42.19 billion, a P/E ratio of 48.49, a P/E/G ratio of 3.83 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. IDEXX Laboratories’s revenue for the quarter was up 3.6% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.71 earnings per share. Equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other IDEXX Laboratories news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the transaction, the director now directly owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the company. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the stock a “hold” rating in a report on Monday, May 19th. Leerink Partners lifted their target price on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the stock an “outperform” rating in a research report on Wednesday, June 11th. Morgan Stanley upped their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the company an “overweight” rating in a research report on Monday, May 5th. Finally, Wall Street Zen lowered shares of IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Friday, May 30th. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $546.00.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.